Lung Function Testing in Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed solid tumor
• •* Locally advanced or metastatic disease
• •Disease progressed on or after standard therapy OR there is no standard therapy for the malignancy
• •* Standard therapy is defined as first- or second-line therapy that has been shown to provide clinical benefit
• •Life-long non-smoker
• •No lung metastasis and/or pleural effusion causing signs or symptoms that impact patient performance status
• •PATIENT CHARACTERISTICS:
• •ECOG performance status 0-1
• •Body mass index ≤ 35
• •No concurrent uncontrolled illness including, but not limited to, the following:
• •* Ongoing or active infection
• •* Symptomatic congestive heart failure
• •* Unstable angina pectoris
• •* Ventricular arrhythmia
• •* Psychiatric illness or social situation that would limit compliance with study requirements
• •No uncontrolled chest or abdominal pain
• •No oral or facial pain exacerbated by an oral device
• •No stress incontinence
• •No COPD, interstitial lung disease, pulmonary embolism, or hemorrhage within the past 6 months
• •No history of pulmonary fibrosis or pulmonary hypertension
• •No oxygen requirement at baseline
• •No asthma
• •No occupational lung disease, including, but not limited to, asbestos exposure
• •No polycythemia
• •No history of connective tissue disease
• •PRIOR CONCURRENT THERAPY:
• •No prior radiotherapy to the lung
• •At least 6 months since prior lung surgery
• •No prior amiodarone hydrochloride
• •No prior high-dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation
• •No concurrent combination antiretroviral therapy for HIV-positive patients